Zoetis’ (ZTS) Buy Rating Reiterated at Jefferies Group

Jefferies Group reiterated their buy rating on shares of Zoetis (NYSE:ZTS) in a research note issued to investors on Friday. The firm currently has a $96.00 price target on the stock. Jefferies Group also issued estimates for Zoetis’ Q1 2018 earnings at $0.71 EPS, FY2018 earnings at $3.07 EPS, FY2019 earnings at $3.56 EPS, FY2020 earnings at $4.11 EPS, FY2021 earnings at $4.56 EPS and FY2022 earnings at $5.09 EPS.

Several other analysts have also recently issued reports on ZTS. Cantor Fitzgerald set a $85.00 target price on Zoetis and gave the company a buy rating in a report on Tuesday, December 26th. Craig Hallum restated a buy rating and issued a $85.00 target price (up from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Citigroup upgraded Zoetis from a neutral rating to a buy rating and set a $85.00 target price for the company in a report on Thursday, January 4th. Zacks Investment Research cut Zoetis from a buy rating to a hold rating in a report on Saturday, January 6th. Finally, BMO Capital Markets restated a hold rating on shares of Zoetis in a report on Monday, January 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company. Zoetis has a consensus rating of Buy and an average price target of $80.89.

How to Become a New Pot Stock Millionaire

Shares of NYSE:ZTS opened at $83.57 on Friday. The company has a debt-to-equity ratio of 2.77, a current ratio of 3.85 and a quick ratio of 2.55. The firm has a market capitalization of $40,741.90, a price-to-earnings ratio of 34.82, a P/E/G ratio of 1.88 and a beta of 0.96. Zoetis has a 52-week low of $53.00 and a 52-week high of $85.73.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.47 EPS. equities analysts expect that Zoetis will post 3.05 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be paid a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio (DPR) is presently 20.83%.

In related news, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the transaction, the executive vice president now owns 49,919 shares of the company’s stock, valued at approximately $4,044,437.38. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The disclosure for this sale can be found here. In the last ninety days, insiders sold 112,952 shares of company stock worth $9,219,843. Corporate insiders own 0.35% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Daiwa SB Investments Ltd. lifted its stake in Zoetis by 92.0% during the 4th quarter. Daiwa SB Investments Ltd. now owns 18,152 shares of the company’s stock worth $1,308,000 after acquiring an additional 8,696 shares in the last quarter. BLB&B Advisors LLC lifted its stake in Zoetis by 5.2% during the 4th quarter. BLB&B Advisors LLC now owns 50,460 shares of the company’s stock worth $3,635,000 after acquiring an additional 2,478 shares in the last quarter. Navellier & Associates Inc acquired a new position in Zoetis during the 4th quarter worth about $606,000. Lombard Odier Asset Management Switzerland SA lifted its stake in Zoetis by 13.8% during the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 279,676 shares of the company’s stock worth $20,148,000 after acquiring an additional 34,000 shares in the last quarter. Finally, Amalgamated Bank lifted its stake in Zoetis by 9.5% during the 4th quarter. Amalgamated Bank now owns 64,901 shares of the company’s stock worth $4,675,000 after acquiring an additional 5,633 shares in the last quarter. 92.44% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/16/zoetis-zts-buy-rating-reiterated-at-jefferies-group.html.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply